1. Home
  2. MGTX

as of 02-25-2026 4:00pm EST

$7.84
+$0.14
+1.82%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Founded: 2015 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 610.1M IPO Year: 2018
Target Price: $23.83 AVG Volume (30 days): 308.3K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.61 EPS Growth: -42.28
52 Week Low/High: $4.73 - $9.73 Next Earning Date: 01-01-0001
Revenue: $33,279,000 Revenue Growth: 137.42%
Revenue Growth (this year): -20.23% Revenue Growth (next year): 569.48%
P/E Ratio: -4.78 Index: N/A
Free Cash Flow: -109450000.0 FCF Growth: N/A

AI-Powered MGTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 71.79%
71.79%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: